Literature DB >> 17056014

KAP1 dictates p53 response induced by chemotherapeutic agents via Mdm2 interaction.

Koji Okamoto1, Issay Kitabayashi, Yoichi Taya.   

Abstract

KAP1 recruits many proteins involved in gene silencing and functions as an integral part of co-repressor complex. KAP1 was identified as Mdm2-binding protein and shown to form a complex with Mdm2 and p53 in vivo. We examined the role of KAP1 in p53 activation after the treatment of cells with different types of external stresses. KAP1 reduction markedly enhanced the induction of p21, a product of the p53 target gene, after treatment with actinomycin D or gamma-irradiation, but not with camptothecin. Treatment with actinomycin D, but not with camptothecin, augmented the interaction of p53 with Mdm2 and KAP1. Further, KAP1 reduction in actinomycin D-treated cells facilitated cell cycle arrest and negatively affected clonal cell growth. Thus, the reduction of KAP1 levels promotes p53-dependent p21 induction and inhibits cell proliferation in actinomycin D-treated cells. KAP1 may serve as a therapeutic target against cancer in combination with actinomycin D.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17056014     DOI: 10.1016/j.bbrc.2006.10.022

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  37 in total

1.  Expression of KAP1 in epithelial ovarian cancer and its correlation with drug-resistance.

Authors:  Mingqiu Hu; Xin Fu; Yanfen Cui; Shilei Xu; Yue Xu; Qiuping Dong; Lu Sun
Journal:  Int J Clin Exp Med       Date:  2015-10-15

2.  Mdm2 and MdmX as Regulators of Gene Expression.

Authors:  Lynn Biderman; James L Manley; Carol Prives
Journal:  Genes Cancer       Date:  2012-03

3.  Novel activity of KRAB domain that functions to reinforce nuclear localization of KRAB-containing zinc finger proteins by interacting with KAP1.

Authors:  Wei Wang; Jinyang Cai; Yingliang Wu; Li Hu; Zongyun Chen; Jun Hu; Ze Chen; Wenxin Li; Mingxiong Guo; Zan Huang
Journal:  Cell Mol Life Sci       Date:  2013-05-12       Impact factor: 9.261

4.  KAP-1 is overexpressed and correlates with increased metastatic ability and tumorigenicity in pancreatic cancer.

Authors:  Chao Yu; Lei Zhan; Jianxin Jiang; Yaozhen Pan; Hong Zhang; Xu Li; Feng Pen; Min Wang; Renyi Qin; Chenyi Sun
Journal:  Med Oncol       Date:  2014-05-27       Impact factor: 3.064

5.  Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression.

Authors:  Kristen E Olberding; Xiaoli Wang; Yanglong Zhu; Jianmin Pan; Shesh N Rai; Chi Li
Journal:  Cancer Biol Ther       Date:  2010-11-01       Impact factor: 4.742

6.  SUMOylation of the transcriptional co-repressor KAP1 is regulated by the serine and threonine phosphatase PP1.

Authors:  Xu Li; H Helen Lin; Hanqing Chen; Xingzhi Xu; Hsiu-Ming Shih; David K Ann
Journal:  Sci Signal       Date:  2010-04-27       Impact factor: 8.192

7.  MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases.

Authors:  Jennifer M Doyle; Jinlan Gao; Jiawei Wang; Maojun Yang; Patrick Ryan Potts
Journal:  Mol Cell       Date:  2010-09-24       Impact factor: 17.970

8.  miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma.

Authors:  Shyamal D Weeraratne; Vladimir Amani; Adrianne Neiss; Natalia Teider; Deborah K Scott; Scott L Pomeroy; Yoon-Jae Cho
Journal:  Neuro Oncol       Date:  2010-12-22       Impact factor: 12.300

9.  Comprehensive evaluation of a novel nuclear factor-kappaB inhibitor, quinoclamine, by transcriptomic analysis.

Authors:  W-Y Cheng; J-C Lien; C-Y Hsiang; S-L Wu; C-C Li; H-Y Lo; J-C Chen; S-Y Chiang; J-A Liang; T-Y Ho
Journal:  Br J Pharmacol       Date:  2009-04-30       Impact factor: 8.739

Review 10.  Emerging roles of the MAGE protein family in stress response pathways.

Authors:  Rebecca R Florke Gee; Helen Chen; Anna K Lee; Christina A Daly; Benjamin A Wilander; Klementina Fon Tacer; Patrick Ryan Potts
Journal:  J Biol Chem       Date:  2020-09-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.